NEW YORK – Sunesis Pharmaceuticals and Viracta Therapeutics announced on Monday that the two drugmakers will merge in an all-stock transaction and form a precision oncology-focused company publicly listed under Viracta's name.
The combined company, which will be headquartered in Cardiff, California, will advance Viracta's precision oncology pipeline of products against virus-associated cancers, including nanatinostat for the treatment of Epstein-Barr virus (EBV)-positive relapsed and refractory lymphomas.